-
公开(公告)号：EP4317409A1
公开(公告)日：2024-02-07
申请号：EP22780271.7
申请日：2022-03-18
发明人： SAWABATA, Noriyoshi , MORITA, Kohei , OBAYASHI, Chiho , SAKAGUCHI, Hirokazu , TOMINAGA, Yoshiaki , ARAKANE, Toru , MORIOKA, Satoko , NODA, Yohei
IPC分类号： C12M3/04 , B01D39/00 , C12M3/06 , C12N5/071 , C12N5/0775 , C12N5/078 , C12N5/0789 , C12N5/09 , C12N5/095 , C12Q1/02 , G01N1/04
摘要： A filter having a plurality of filter pores penetrating one surface and the other surface of the filter, in which the filter pore has a first opening on the one surface and a second opening on the other surface, a ratio of a major axis diameter L1 to a minor axis diameter W1 of the first opening is 1.00 or more and 1.20 or less, the minor axis diameter W1 is 7.0 µm or more and 9.0 µm or less, a ratio of a major axis diameter L2 to a minor axis diameter W2 of the second opening is 1.00 or more and 1.20 or less, and a ratio of the minor axis diameter W2 to the minor axis diameter W 1 and a ratio of the major axis diameter L2 to the major axis diameter L1 are both 1.20 or more and 1.50 or less.
-
2.发明公开
公开(公告)号：EP4194005A1
公开(公告)日：2023-06-14
申请号：EP21861702.5
申请日：2021-08-27
摘要： The present invention is intended to provide a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament does not cause side effects, is excellent in immediate effectiveness, and has a high antidotal effect. Specifically, the present invention relates to a medicament for cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, wherein the medicament comprises, as an active ingredient(s), one or more selected from the group consisting of a heme protein capable of binding to cyanide ions (CN - ), hydrogen sulfide ions (HS - ) and azide ions (N 3 - ), a substance containing a heme protein capable of binding to CN - , HS - and N 3 - , and a heme derivative capable of binding to CN - , HS - and N 3 - . More specifically, the present invention relates to a medicament or a pharmaceutical composition for the treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.
-
公开(公告)号：EP3961211A1
公开(公告)日：2022-03-02
申请号：EP20795805.9
申请日：2020-04-23
发明人： KAWABE, Toshiki , ODA, Yukio , EMMI, Mari , SHIMA, Midori , NOGAMI, Keiji , OGIWARA, Kenichi , SHIMONISHI, Naruto
摘要： Provided is a method by which a titer of a coagulation factor inhibitor can be measured simply and in a short time. The present invention relates to a method for measuring a titer of a coagulation factor inhibitor. The method includes: preparing a mixed specimen containing a subject blood specimen and a normal blood specimen; heating the mixed specimen and acquiring a coagulation reaction curve for the heated mixed specimen; acquiring a coagulation reaction curve for the mixed specimen that has not been heated; calculating a parameter related to the coagulation reaction curve of the mixed specimen that has not been heated as a first parameter; calculating a parameter related to the coagulation reaction curve of the heated mixed specimen as a second parameter; and calculating a titer of a coagulation factor inhibitor in the subject blood specimen on the basis of the ratio or the difference between the first parameter and the second parameter.
-
公开(公告)号：EP2810622A1
公开(公告)日：2014-12-10
申请号：EP13743741.4
申请日：2013-01-28
发明人： ANAI, Hiroshi , YUBA, Toshiyasu
IPC分类号： A61F2/82
CPC分类号： A61F2/04 , A61F2/07 , A61F2/24 , A61F2/915 , A61F2002/041 , A61F2002/91575 , A61F2230/0008 , F04C2270/0421
摘要： The purpose of the present invention is to provide a biliary stent making it possible to sufficiently exhibit a valve function while reducing the entire length of the biliary stent as compared to conventional ones. The present invention is a biliary stent (1) including a stent body (10), a tubular membrane (30) on one end of the stent body (10) and having a bile outflow port (34), and two support members (40, 50) which at one end (42, 52) are connected to the one end of the stent body (10) and at the other end (44, 54) are connected to the vicinity of the bile outflow port (34).
摘要翻译： 本发明的目的是提供一种胆道支架，使得与常规胆管支架相比，可以充分发挥瓣膜功能同时减少胆管支架的整个长度。 本发明是一种胆管支架（1），其包括支架主体（10），在支架主体（10）的一端上的管状膜（30），并具有胆汁流出口（34），以及两个支撑构件 ，50），其一端（42,42）与支架主体（10）的一端连接，另一端（44,45）连接到胆汁流出口（34）附近。
-
5.发明公开FETAL HEART POTENTIAL SIGNAL EXTRACTION PROGRAM, FETAL HEART POTENTIAL SIGNAL-DISCRIMINATING APPARATUS AND PREGNANCY MONITORING SYSTEM USING SAME 审中-公开计划用于为FÖTUSHERZPOTENTIALFOR信号选择为一个FÖTUSHERZPOTENTIAL和怀孕监测系统识别信号的提取，设备
公开(公告)号：EP2668897A1
公开(公告)日：2013-12-04
申请号：EP12739383.3
申请日：2012-01-25
IPC分类号： A61B5/0444
CPC分类号： A61B5/02411 , A61B5/04286 , A61B5/0444 , A61B5/4362 , A61B5/6823 , A61B5/7203 , A61B5/7235 , A61B5/7253 , A61B5/7271
摘要： A computer program for extracting a fetal cardiac potential signal includes: a selecting module configured to select, from among multiple biopotential signals, a biopotential signal containing a high proportion of a maternal cardiac potential signal component; an independent component analysis module configured to perform independent component analysis on multiple biopotential signals; a periodic signal detection module configured to detect a signal having periodic peaks among a biopotential signal selected by the selecting module and output signals after independent component analysis, as a peak time signal; an output signal selecting module configured to acquire, as reference input, a biopotential signal that is selected by the selecting module and detected as a peak time signal and also acquire, as comparison input, a peak time signal among output signals after independent component analysis, so as to select an output signal having peak times different from those of the biopotential signal detected as a peak time signal; and a module configured to output a selected output signal.
摘要翻译： 用于提取胎儿心电位信号的计算机程序，包括：模块选择被配置来选择，从在多个生物电势信号，将含有母体心电位信号分量的高比例的生物电势信号的装置; 上被配置为执行在多个生物电势信号的独立分量分析独立分量分析模块; 的周期性信号检测模块，用于检测具有由后独立分量分析的选择模块和输出信号选择的生物电势信号中周期性峰值的信号，作为峰值时间信号; 到用于获取输出信号选择模块，如参考输入，一个生物电势信号没有由选择模块选择并检测为峰值时间信号，从而获取，作为比较输入，经过独立分量分析的输出信号中的峰值的时间信号， 以选择具有高峰时间从那些检测为峰值时间信号的生物电势信号的不同的输出信号; 和一个模块被配置为输出所选择的输出信号。
-
公开(公告)号：EP2915557B1
公开(公告)日：2018-05-09
申请号：EP13850016.0
申请日：2013-11-01
申请人： Cosmed Pharmaceutical Co., Ltd. , Osaka University , Public University Corporation Nara Medical University
发明人： QUAN, Ying-shu , KAMIYAMA, Fumio , SAITO, Mio , NAKAGAWA, Shinsaku , OKADA, Naoki , HIROBE, Sachiko , ASADA, Hideo
CPC分类号： A61K31/203 , A61K9/0021 , A61K31/122 , A61K31/375 , A61M37/00 , A61M2037/0046 , A61K2300/00
摘要： An object to be achieved by the present invention is to provide a microneedle array which is able to supply effectively retinoic acid to the skin and effective in treating pimples, stains or wrinkles. The retinoic acid microneedle array comprises: a microneedle array having a microneedle substrate 5 and microneedles 1 disposed on the microneedle substrate 5; and a drug retained on the microneedles 1 and containing a water-swelling polymer and retinoic acid.
-
公开(公告)号：EP2902787B1
公开(公告)日：2018-03-28
申请号：EP13842222.5
申请日：2013-09-26
CPC分类号： C12Q1/56 , C12N9/6443 , G01N33/86 , G01N2333/755 , G01N2333/96452 , G01N2800/224
摘要： Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.
-
公开(公告)号：EP4110019A1
公开(公告)日：2022-12-28
申请号：EP21756440.0
申请日：2021-02-19
IPC分类号： H05B47/105 , H05B47/16
摘要： An illumination device includes a light emitter configured to emit illumination light and a controller configured to control the light emitter. The controller controls the illumination light such that a first decrease ratio of melanopic illuminance of illumination light during night-time illumination to melanopic illuminance of illumination light during daytime illumination is higher than a second decrease ratio of illuminance of the illumination light during the night-time illumination to illuminance of the illumination light during the daytime illumination.
-
公开(公告)号：EP3205297B1
公开(公告)日：2020-11-04
申请号：EP14908973.2
申请日：2014-12-24
-
公开(公告)号：EP3603670A1
公开(公告)日：2020-02-05
申请号：EP18776553.2
申请日：2018-03-30
发明人： SHIMA, Midori , NOGAMI, Keiji , OGIWARA, Kenichi
摘要： The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and/or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and/or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.017 秒)
